Gujarat Kidney And Super Speciality Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Gujarat Kidney And Super Speciality Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Gujarat Kidney And Super Speciality shares trading at Rs.130 against a market capitalisation of Rs.1,010 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, Gujarat Kidney And Super Speciality enters the Gujarat Kidney And Super Speciality Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Gujarat Kidney And Super Speciality are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Gujarat Kidney And Super Speciality Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Gujarat Kidney And Super Speciality Research at Univest

Gujarat Kidney And Super Speciality (NSE: GKSL) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings ahead of the Gujarat Kidney And Super Speciality Q1 Results FY27 season, forming the base against which the Gujarat Kidney And Super Speciality Q1 Results FY27 estimates in this article are built. This Gujarat Kidney And Super Speciality Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Gujarat Kidney And Super Speciality Q1 FY27 Estimates

Metric	Detail
CMP	Rs.130
Market Cap	Rs.1,010 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.131-148

Univest, a SEBI-Registered Investment Advisor, Tracks Gujarat Kidney And Super Speciality Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Occupancy and ARPOB Trends

Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of Gujarat Kidney And Super Speciality’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Kidney And Super Speciality share price target or faces renewed pressure.

2. Capacity Addition

Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of Gujarat Kidney And Super Speciality’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Kidney And Super Speciality share price target or faces renewed pressure.

3. Case Mix Improvement

Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of Gujarat Kidney And Super Speciality’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Kidney And Super Speciality share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Gujarat Kidney And Super Speciality’s live price and Q1 FY27 result updates.

Key Risks to the Gujarat Kidney And Super Speciality Q1 Results FY27 Outlook

• Slower occupancy ramp-up in newly added capacity affecting near-term margins.
• Regulatory changes to pricing or insurance reimbursement norms.
• Talent cost inflation for specialist doctors and clinical staff.

Recent Performance Context

Detailed recent-quarter financials for Gujarat Kidney And Super Speciality were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Gujarat Kidney And Super Speciality Q1 Results FY27

Gujarat Kidney And Super Speciality shares last traded at Rs.130. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Gujarat Kidney And Super Speciality Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Gujarat Kidney And Super Speciality Q1 Results FY27 trailing-growth framework points to a range of Rs.127-137 for Gujarat Kidney And Super Speciality, contingent on the Gujarat Kidney And Super Speciality Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Gujarat Kidney And Super Speciality Q1 Results FY27 view for Gujarat Kidney And Super Speciality works out to Rs.131-148, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Gujarat Kidney And Super Speciality Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Gujarat Kidney And Super Speciality Q1 Results FY27 analysis would put Gujarat Kidney And Super Speciality in a Rs.138-161 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Gujarat Kidney And Super Speciality Q1 Results FY27 Print

• Revenue and PAT versus the Gujarat Kidney And Super Speciality Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Gujarat Kidney And Super Speciality Q1 Results FY27 narrative.
• Occupancy and ARPOB improvement across hospital and diagnostic networks
• Slower occupancy ramp-up in newly added capacity affecting near-term margins

Conclusion on Gujarat Kidney And Super Speciality Q1 Results FY27

Gujarat Kidney And Super Speciality enters the Q1 FY27 results season trading at Rs.130, with the 12-month Uniresearch target range of Rs.131-148 reflecting a tracking stance. Investors tracking the Gujarat Kidney And Super Speciality Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Gujarat Kidney And Super Speciality Q1 Results FY27

When are Gujarat Kidney And Super Speciality Q1 FY27 results expected?

Ans. Gujarat Kidney And Super Speciality’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Gujarat Kidney And Super Speciality Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Gujarat Kidney And Super Speciality at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Gujarat Kidney And Super Speciality share price target?

Ans. The 12-month Uniresearch estimate for Gujarat Kidney And Super Speciality share price target is Rs.131-148, based on trailing growth and current valuation multiples.

Is Gujarat Kidney And Super Speciality a good buy before Q1 FY27 results?

Ans. Gujarat Kidney And Super Speciality is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Gujarat Kidney And Super Speciality’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.

Where can I track Gujarat Kidney And Super Speciality share price live?

Ans. Gujarat Kidney And Super Speciality share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.